A Phase 2 Clinical Trial Evaluating the Incidence of Upper Gastrointestinal Mucosal Damage Following Administration of Either PL3100 or Naproxen in Subjects Who Are at Risk for Developing NSAID-Associated GI Damage.

Trial Profile

A Phase 2 Clinical Trial Evaluating the Incidence of Upper Gastrointestinal Mucosal Damage Following Administration of Either PL3100 or Naproxen in Subjects Who Are at Risk for Developing NSAID-Associated GI Damage.

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Apr 2016

At a glance

  • Drugs Naproxen/phosphatidylcholine (Primary) ; Naproxen
  • Indications Arthritis; Pain
  • Focus Adverse reactions
  • Sponsors PLx Pharma
  • Most Recent Events

    • 15 Feb 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 08 Nov 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 12 Jul 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top